Clozapine-induced myopericarditis is a well-described adverse drug reaction. Clozapine is also the most effi cacious agent in refractory schizophrenia. We report a case of a patient who was successfully re-trialled on clozapine two years after developing myopericarditis, after which multiple lines of alternative treatment failed. We propose a protocol for safely attempting a re-trial of clozapine in such cases.
Get full access to this article
View all access options for this article.
References
1.
LaylandJJDLiewPriorDL.Clozapine-induced cardiotoxicity: a clinical update.Med J Aust2009; 190: 190-3.
2.
KilianJGKKerrLawrenceCMyocarditis and cardiomyopathy associated with clozapine.Lancet1999; 354: 1841-5.
3.
RonaldsonKJPBFitzgeraldTaylorAJObservations from 8 cases of Clozapine rechallenge after development of myocarditis.J Clin Psychiatry2012; 73: 252-4.
4.
ManuPSarpalDMuirOKaneJWhen can patients with potentially life-threatening aderse effects be rechallenged with clozapine? A systematic review of the published literature.Schizophr Res2012; 134: 180-6.
5.
MeltzerHYLAlphsGreenAIClozapine Treatment for suicidality in schizophrenia International suicide Prevention Trial (IntersePT). Arch Gen Psychiatry2003; 60: 82-91.
6.
HaasSJRHillKrumHClozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.Drug Saf2007; 30: 47-57.
